Skip to main content

Top Menu

  • Contact
  • Media
  • Careers
  • Staff
  • About Us
    • About CCTG
    • CCTG Strategic Plan 2022-2027
    • Committee Leadership
    • CCTG Scientific Leadership
    • CCTG Management
    • Careers at CCTG
    • CCTG policies
    • Contact us
  • Patients & Families
    • Patients & Families
    • Patient Representatives Committee
    • Patients as research partners
    • Resources for patients & families
    • Clinical trials - public
  • Disease Site Listings - Public

    Disease Site Listings - Public

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Multi-Site
    • Sarcoma
    • Symptom Control
  • Disease Site Listings - Members

    Disease Site Listings - Members

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
  • Clinical Trials
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Clinical trials - overview
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Publications

    Mobile CCTG Clinical Trials

    • Member Trial Pages
    • Public Trial Pages
    • Publications
    SPECT-CT Guided ELEctive Contralateral Neck Treatment (Select) for Patients with Lateralized Oropharyngeal Cancer.

    Now open, the HN11 SELECT trial looking at a personalized radiotherapy treatment for throat cancer

    CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)

    More >>

    Recently Activated Trials

    BLC5

    MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

    More >>

    HN11

    SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

    More >>

    MEC6

    Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma

    More >>
  • Member Resources

    Member Links

    • Current trials
    • Disease site & IND committees
    • Standing committees
    • Leadership resources
    • Become a member
    • Funding information
    • Compliance & oversight
    • Audit, inspection & partner compliance
    • Generic protocols
    • Group newsletter: CCTG Connection
    • Help & Support
    • Terms of reference
    Expansion of the Tissue Bank facilities

    Expansion of the Tissue Bank facilities

    The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.

    More >>

    Planned Trials

    AL6

    MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

    ALC7

    Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials

    ALC8

    Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

    ALC9

    Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

    CRC10

    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    EN10

    Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

    Disease Site Committees

    • Brain
    • Breast
    • Gastro-Intestinal
    • Gynecologic
    • Genito-Urinary
    • Head & Neck Working Group
    • Hematologic
    • IND
    • IND Executive
    • Lung Disease
    • Melanoma
    • Sarcoma
  • Meetings & Education
    • Spring meeting of participants
      • CCTG recognition awards
      • Maria Ricci Memorial Lecture
    • New investigator cancer trials practicum
    • New investigator clinical trials course
    • Fellowships
    • The Frances A Shepherd Award
    • Conference presentations
  • Search

  • Donate
  • Toolbox
    • Applications
    • >>  EDC (Medidata Rave)
    • >>  iMedidata
    • >>  Mango
    • >>  Ripple
    • >>  Lettuce
    • >>  Sprout (ePRO)
    • Exposure Reporting
    • >>  CTEP website
    • >>  CTCAE v5.0 booklet
    • >>  CTCAE v4.0 booklet
    • >>  CTCAE v3.0 booklet
    • >>  CTEP-AERS reporting
    • >>  EDC SAE (paper report)
    • >>  Pregnancy reporting form
    • >>  Exposure reporting form
    • Support
    • >>  Passwords management
    • >>  CCTG contacts
    • >>  Support information
    • Tissue Bank
    • >>  Tissue Bank
    • >>  Inventory
    • >>  Tissue research
    • Reports
    • >>  Accrual utility (Monthly site accrual)
    • >>  Safety reports
    • >>  Papaya
    • >>  Ethics
    • >>  Trial closure
    • Data Management
    • >>  Baseline symptoms & adverse events
    • >>  Concomitant medications template
    • >>  SI conversion table
    • >>  iRECIST & RECIST guidelines
    • Training
    • >>  NIH ethics training
    • >>  Division 5 part C
    • >>  Good clinical practice
    • >>  Site training
    • >>  Supplementary training
  • Contact Us
  • Media
  • Staff

  For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Conference Presentations

Abstracts presented at the 2022 ASCO Annual Meeting
June 3-7, 2022
Abstracts presented at the 63rd ASH Annual Meeting
December 11-14, 2021
Abstracts presented at the Annual San Antonio Breast Cancer Symposium
Henry B. Gonzalez Convention Center
San Antonio, Texas
December 6-10, 2022
  • Partnerships 600+ trials in 40+ countries
  • IND Program 38+ years experience in 205+ drug trials
  • Tissue Bank 300,000+ samples from 120+ trials
  • Network 2100+ investigators at 85+ sites
  • Become a CCTG Investigator
CCTG Strategic Plan 2022-2027
CCTG Strategic Plan 2022-2027

Footer Menu

  • About us
  • Patients & Families
  • Clinical trials
  • Member resources
  • Meetings & Education
  • Publications
  • Toolbox
  • Contact us
  • Media centre
  • Staff
  • Careers

CANADIAN CANCER TRIALS GROUP

Cancer Research Institute
Queen's University

10 Stuart Street
Kingston, Ontario
Canada K7L 3N6

A NATIONAL PROGRAM OF THE:

 

OPERATIONS AND STATISTICAL CENTRE LOCATED AT:

PROUDLY AFFILIATED WITH:

As a national cooperative group, CCTG recognizes that Canada is situated on Indigenous lands, we acknowledge that the Operations and Statistics Centre, located at Queen’s University, is located on traditional Anishinaabe and Haudenosaunee Territory.
© Canadian Cancer Trials Group, 2021 | Terms & Conditions Facebook LinkedIn TwitterYouTube